Who this procedure is actually for

Fresh osteochondral allograft (OCA) transplantation is not a routine first step. It sits near the top of the ankle cartilage repair ladder, reserved for lesions that are too large, too structurally complex, or too damaged for simpler approaches to succeed.

The clearest signal is lesion size. Research by Chuckpaiwong et al. (2008) followed 105 ankle osteochondral lesions and found that microfracture — the standard first-line procedure — produced only a 3% success rate once a lesion reached 15 mm or more in average diameter. A corroborating study by Choi et al. (2009) translated this into an MRI-based cut-off of 150 mm²: above that area, bone marrow stimulation reliably fails. The 2–4 cm² band is where fresh OCA transplantation is most commonly performed.

Size is not the only consideration. A consultant would also move towards OCA when:

• a prior repair procedure — microfracture or autograft — has already broken down (the revision setting)
• the lesion includes subchondral cysts requiring both cartilage and bone restoration simultaneously
• the defect is uncontained, making a matched autograft plug impractical
• advancing age or other factors reduce the likely benefit from bone marrow stimulation

In short: if simpler options are unlikely to succeed given the specific lesion profile, or have already been tried, OCA becomes the logical next conversation.

How size and lesion shape determine the recommendation

The thresholds outlined above — 15 mm diameter and 150 mm² on MRI — mark the outer boundary of bone marrow stimulation, but size alone does not capture the whole clinical picture. Lesion shape and depth each determine whether a given technique can realistically restore the joint surface.

Autologous osteochondral transplantation (OATS or mosaicplasty) addresses lesions in the 1–2 cm² range, and a mosaic arrangement can extend this to roughly 4 cm². The technique relies on cylindrical donor plugs harvested from elsewhere in the joint, and that circular geometry conforms poorly to defects without a surrounding bony wall. An uncontained lesion — one that extends to the edge of the articular surface without a raised rim — cannot be reliably filled by plug geometry, regardless of total area. The plug simply has nothing to seat against.

Subchondral cysts introduce a distinct structural problem. When meaningful bone loss underlies the cartilage defect, a procedure targeting only the surface layer leaves the structural foundation untreated. A fresh OCA graft replaces the full depth of the osteochondral unit — articular cartilage and the supporting bone beneath — in a single procedure. No other restoration technique addresses both layers simultaneously in this way, which is why cystic talar lesions represent a particularly clear-cut morphological indication.

These factors often compound one another. A cystic talar lesion exceeding 15 mm that has already failed microfracture presents all three triggers at once: size beyond the bone marrow stimulation ceiling, bone loss requiring structural restoration, and frequently an uncontained border. That combination places OCA firmly as the logical next step.

Why the allograft must be fresh, not frozen

Chondrocytes — the cells that maintain cartilage — are the reason the word 'fresh' matters so much here. In a frozen allograft, those cells are destroyed by the freezing process; the structural scaffold arrives intact but biologically inert. A fresh graft, by contrast, contains living chondrocytes within a largely preserved extracellular matrix, and retrieval studies of transplanted tissue confirm that viable cells persist many years after implantation when the graft is handled correctly.

Viability, however, degrades with time. After procurement, chondrocyte survival begins to fall noticeably from around Day 14 and drops below the accepted clinical threshold — 70% viable cells — by Day 28. That creates a transplantation window of roughly 14 to 28 days from donor procurement to surgery. In practice, this means the procedure cannot be booked like a routine elective operation; it depends on tissue availability through a regulated bank, and scheduling is arranged around graft readiness rather than purely around the calendar. Patients should understand this upfront — it is a coordination factor, not a clinical risk in itself.

One reassurance worth stating plainly: two retrieval studies of failed human fresh OCA transplants found little or no histological evidence of immune-mediated response, and no sign of frank rejection. The procedure does not require immunosuppression, and the immune safety profile appears well supported by the available tissue-level evidence.

Where OCA sits in the ankle cartilage repair pathway

Ankle osteochondral lesions are treated along a progression where each step is chosen because the one before it has reached its limit — not because surgeons are working through options arbitrarily.

At the base of that ladder sits bone marrow stimulation (microfracture). For small primary lesions under roughly 1.5 cm in diameter, it has historically produced acceptable early results. The limitation is what it produces: fibrocartilage rather than the hyaline cartilage it replaces. Evidence shows this repair tissue begins to deteriorate at two to three years, and the microfracture process itself damages the subchondral bone plate — a complication that can narrow the options available if a further procedure is later needed.

OATS and mosaicplasty take over at the intermediate range, broadly 1–4 cm² where autograft geometry allows a reasonable fit. Zengerink et al.'s systematic review of 243 patients reported an 87% success rate, making OATS a solid option for the right anatomy. Donor-site morbidity and the geometric constraints described in the previous section mark where this approach runs out.

For defects of 3 cm² or larger, MACI has shown superior outcomes to microfracture in the SUMMIT trial, though the data were collected in knee populations; whether this translates equally to the ankle is less well established, and a consultant assessment is needed to determine whether it applies to a specific lesion.

OCA sits at the top of this ladder because it is the only technique that addresses both cartilage and deep subchondral bone in a single procedure — a capacity that becomes essential for the large, cystic, uncontained, or previously treated lesions where all other options have run out.

What the operation involves for the ankle specifically

Unlike the knee, where the femoral condyle is relatively accessible, the talar dome sits deep within the ankle mortise and cannot be reached directly without first moving bone out of the way. For the medial talar dome — where the majority of osteochondral lesions occur — surgeons perform a chevron-type medial malleolar osteotomy: the medial malleolus is cut in a controlled V-shape, the flap hinged aside to expose the lesion, then fixed back with screws once the graft is seated. Lateral lesions call for a tibial trapezoidal osteotomy to achieve equivalent exposure.

This is meaningfully more involved than an arthroscopic ankle procedure. A patient consenting to ankle OCA is consenting to two overlapping interventions: the graft itself and an osteotomy that carries its own healing requirements. Recovery time reflects both — the osteotomy must unite reliably before full weight-bearing is appropriate, not only the graft interface.

Once access is established, the allograft is sized to match the prepared lesion bed precisely and seated using a press-fit technique, relying on the interference fit and surrounding bone rather than internal fixation of the cartilage layer.

The added surgical complexity is not a reason to avoid OCA when it is the right procedure — but it makes pre-operative planning and specialist experience in ankle reconstruction important factors in shared decision-making.

Outcomes: what the evidence shows and where gaps remain

The most robustly documented long-term outcomes for fresh OCA come from knee populations. Gross et al. (2008) followed 149 knees over a mean six years: approximately 75% of patients returned to sport or recreational activity, and 71% achieved very good or excellent function. These figures represent the technique's strongest evidence base — a meaningful benchmark rather than a direct ankle prediction.

Ankle-specific OCA series have been published and inform current practice, though they come from smaller cohorts than the knee literature. The most patient-relevant frame is not a headline success rate but the procedure's actual goals: meaningful pain reduction, improved functional mobility, and — in most cases — delay or avoidance of joint replacement.

One biological finding carries particular weight for long-term expectations. Retrieval studies of failed human fresh OCA transplants showed no histological evidence of immune-mediated rejection, supporting the view that graft integration, where it occurs, is durable rather than subject to chronic immune erosion over time.

Choosing not to treat a large, symptomatic osteochondral lesion is not a neutral position. Progressive subchondral bone loss and worsening joint damage tend to close off options that remain available now. For patients who have reached the point where OCA is the appropriate recommendation, the meaningful comparison is not the procedure against comfortable inaction — it is intervention against a trajectory that increasingly limits future choices. That trade-off is central to the assessment conversation.

Patients can book a consultant-led assessment with the MSK Doctors team — no GP referral needed — at mskdoctors.com.